Real-World Pharmacokinetics in Older Multimorbid Patients: Clinical Implications and Evidence-Based Approaches

Abstract

The pharmacokinetics (PK) of medications in older multimorbid patients present unique challenges due to physiological changes associated with aging and the complex interplay of multiple chronic diseases and polypharmacy. This review synthesizes recent evidence on the impact of multimorbidity on drug absorption, distribution, metabolism, and excretion in the aging population, with a focus on real-world data and clinical practice. We discuss epidemiology, pathophysiological mechanisms, risk factors, clinical features, diagnostic approaches, and evidence-based management strategies, including pharmacological considerations, recent advances, and guideline recommendations. The review aims to provide healthcare professionals with actionable insights to optimize pharmacotherapy, minimize adverse drug reactions, and improve outcomes in older patients with multimorbidity.

Introduction

Older adults with multiple chronic conditions represent a growing demographic in clinical practice. The real-world pharmacokinetics in this population is influenced by age-related physiological changes and the cumulative burden of comorbid diseases, which can alter drug handling and response. Understanding these changes is critical for safe and effective pharmacotherapy. Traditional clinical trials often exclude these complex patients, making real-world evidence essential for guiding clinical decisions. This article provides an in-depth analysis of the pharmacokinetic challenges and solutions in older multimorbid patients, drawing from recent research and consensus guidelines.

Epidemiology / Disease Burden

Globally, the population aged 65 and older is expanding at an unprecedented rate. According to the World Health Organization, multimorbidity—defined as the coexistence of two or more chronic diseases—affects over 60% of older adults. This demographic is at increased risk for adverse drug reactions (ADRs) due to altered drug metabolism and polypharmacy, with studies indicating up to 30% of hospital admissions in this group are medication-related. The cumulative effect of multiple diseases compounds the complexity of pharmacokinetics, impacting drug exposure and therapeutic outcomes.

Pathophysiology

Aging induces a range of physiological changes that significantly affect the pharmacokinetic processes of absorption, distribution, metabolism, and excretion (ADME). Gastric pH increases and gastrointestinal motility decreases with age, altering oral drug absorption. Reduced lean body mass, increased fat stores, and decreased plasma albumin impact drug distribution. Hepatic metabolism is compromised by decreased liver mass and hepatic blood flow, which are further exacerbated by comorbidities such as heart failure or hepatic impairment. Renal excretion is frequently impaired due to age-related decline in glomerular filtration rate (GFR) and the prevalence of chronic kidney disease. The synergistic impact of these changes is amplified in those with multiple comorbid conditions, leading to unpredictable drug levels and increased risk of toxicity.

Risk Factors

Several factors contribute to altered pharmacokinetics in older multimorbid patients. Polypharmacy is a major risk factor, with the average older adult taking five or more medications. Comorbidities such as diabetes, cardiovascular disease, and chronic kidney disease further modulate drug handling. Genetic polymorphisms affecting drug-metabolizing enzymes, frailty, malnutrition, and cognitive impairment also play pivotal roles. Additionally, functional decline, reduced physiological reserve, and fluctuations in disease states contribute to PK variability and complicate medication management.

Clinical Features

Real-world manifestations of altered pharmacokinetics in older multimorbid patients include increased sensitivity to standard drug doses, delayed onset or prolongation of drug action, and a heightened risk of ADRs, including falls, delirium, and organ dysfunction. Non-specific symptoms such as confusion, lethargy, and functional decline are common and often mistaken for disease progression rather than drug effect. Recognition of these features requires a high index of suspicion and continuous monitoring, particularly during transitions of care or medication adjustments.

Diagnosis

Assessment of altered pharmacokinetics in clinical practice involves comprehensive medication reconciliation, review of renal and hepatic function, and evaluation of drug-drug and drug-disease interactions. Therapeutic drug monitoring (TDM) is recommended for medications with narrow therapeutic indices. Geriatric assessment tools, such as the STOPP/START and Beers Criteria, aid in identifying potentially inappropriate medications. Pharmacogenomic testing is emerging as a diagnostic adjunct, especially in patients with unexplained drug responses or toxicity.

Treatment & Management

Management requires individualized therapy based on regular assessment of organ function, comorbid conditions, and ongoing risk-benefit analysis. Dose adjustments should be guided by renal and hepatic function, with preference for medications with wider therapeutic windows. De-prescribing unnecessary medications, simplifying regimens, and prioritizing non-pharmacological interventions are key strategies. Integrated care models, involving pharmacists and geriatric specialists, enhance medication safety. Patient and caregiver education on adherence and monitoring for ADRs is crucial for optimizing outcomes.

Recent Advances / Emerging Therapies

Recent advances include the use of population-based PK modeling and physiologically based pharmacokinetic (PBPK) simulations to predict drug exposure in multimorbid older adults. Electronic health record (EHR)-integrated clinical decision support tools are increasingly used to identify high-risk drug combinations and recommend dose modifications. Novel biomarkers for renal and hepatic function, as well as point-of-care TDM, are being developed to enable real-time PK assessment. Personalized medicine approaches, leveraging pharmacogenomics and machine learning algorithms, show promise in tailoring therapy for this complex population.

Guideline Recommendations

Guidelines from the American Geriatrics Society, European Society of Cardiology, and other professional bodies emphasize the importance of individualized dosing, regular medication review, and avoidance of high-risk medications in older multimorbid patients. They advocate for interdisciplinary care, routine assessment of renal and hepatic function, and the use of validated screening tools for polypharmacy management. Implementation of deprescribing protocols and incorporation of real-world data into clinical algorithms are recommended to enhance safety and efficacy of pharmacotherapy in this population.

Conclusion

The management of pharmacokinetics in older multimorbid patients requires a nuanced, evidence-based approach that accounts for age-related physiological changes, disease burden, and polypharmacy. Recent advances in PK modeling, personalized medicine, and guideline-driven care are reshaping clinical practice. Clinicians must remain vigilant for atypical drug responses and incorporate real-world data to optimize therapeutic outcomes and minimize risks. Ongoing research and collaborative care models are essential to address the unique needs of this vulnerable population and to ensure safe, effective pharmacotherapy in the real-world setting.